
|Articles|May 1, 2003
ISTA to try again after FDA panel rejects Vitrase
Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
PRIMA retinal implant restores vision in patients with advanced GA
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































